
BETAGLUE TECHNOLOGIES SPA
Primary tabs
About your organization / profile
BetaGlue is developing an innovative "radiotherapy from within", personalized and cost-effective anti-tumoural platform technology called BAT-90. BAT-90 maximises the therapeutic index of loco-regional treatment by eliminating off-target radiation dose in a simple and easy to use product. The product aims to provide a radiotherapeutic treatment option for a range of solid tumour types including: unresectable hepatocellular carcinoma (HCC) and locally advanced and borderline resectable pancreatic cancer (PDAC) patients, where in the first-line setting, there exists a major unmet clinical need. Through the percutaneous administration of BAT-90 under radiological guidance (usually ultrasound) BAT-90 overcomes the accessibility and off-target side effect limitations of external beam radiotherapy, forms of brachytherapy, proton beam radiotherapy trans-arterial radio-embolisation and microwave ablation. BAT-90 has already demonstrated safety and preliminary effectiveness in first-in-human clinical studies.
Network (0)
There are no organizations in the network.
Recent activities

BETAGLUE TECHNOLOGIES SPA is now a member of the EIC ACCESS+ community.

BETAGLUE TECHNOLOGIES SPA is now a member of the EIC Ecosystem Partnerships and Co-Investment Support Programme community.

BETAGLUE TECHNOLOGIES SPA has taken its fundraising offline.

The pitchdeck document has been updated in the dataroom.

BETAGLUE TECHNOLOGIES SPA has published fundraising documents.

BETAGLUE TECHNOLOGIES SPA is now a member of the EEN2EIC - Seal of Excellence community.

BETAGLUE TECHNOLOGIES SPA is now a member of the EEN2EIC - Seal of Excellence community.

Marta Biffi has joined BETAGLUE TECHNOLOGIES SPA.